Related Experiment Video

Updated: Mar 29, 2026

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

3.3K

Steroids in Central Retinal Vein Occlusion: Is There a Role in Current Treatment Practice?

Mohammed Ashraf1, Ahmed A R Souka1

  • 1Ophthalmology Department, Faculty of Medicine, Khartoum Square, El Azarita, Alexandria, Egypt.

Journal of Ophthalmology
|December 5, 2015
PubMed

Insights

Steroids are rarely used for central retinal vein occlusion (CRVO) due to the proven efficacy and safety of anti-VEGF treatments. This review examines if steroids still have a place in CRVO management.

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Vascular Disorders

Background:

  • Central retinal vein occlusion (CRVO) is a significant cause of vision loss.
  • Anti-VEGF therapies are now the standard of care for CRVO.
  • Steroids carry risks such as increased intraocular pressure and cataract formation.

Purpose of the Study:

  • To review the current role of steroids in managing central retinal vein occlusion (CRVO).
  • To evaluate steroid use as monotherapy, adjunct, or alternative treatment for CRVO.
  • To determine if steroids remain a viable option in the evolving landscape of CRVO treatment.

Main Methods:

  • Review of recent large-scale randomized control trials (RCTs).
  • Analysis of data on anti-VEGF efficacy and safety in CRVO.
  • Examination of studies on steroid use in CRVO management.

Main Results:

  • Anti-VEGFs have demonstrated established efficacy and safety for CRVO.
  • Steroid use in CRVO has significantly decreased.
  • Concerns regarding steroid-induced side effects limit their application.

Conclusions:

  • The role of steroids in CRVO management is significantly diminished with the advent of anti-VEGFs.
  • Steroids may be considered in specific, limited circumstances for CRVO.
  • Further research may clarify nuanced roles for steroids in CRVO treatment.

More Related Videos

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy11:03

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

10.6K
Intravitreal Injections in the Ovine Eye03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.3K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
607
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K